Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Ophthalmology Science
|
May 8, 2026
Reply
Mariella Saludares, Zachary Wennberg-Smith, Gala Beykin, et al.
Ophthalmology Science
|
January 26, 2026
A Phase I Randomized Trial of Topical Insulin for Glaucoma: Safety and Efficacy Outcomes
Mariella Saludares, Zachary Wennberg-Smith, Gala Beykin, et al.
Investigative Ophthalmology & Visual Science
|
August 18, 2021
Analysis of the Aqueous Humor Proteome in Patients With Age-Related Macular Degeneration
Batya Rinsky, Gala Beykin, Michelle Grunin, et al.
Journal of Glaucoma
|
June 13, 2022
Structural and Metabolic Imaging After Short-term Use of the Balance Goggles System in Glaucoma Patients: A Pilot Study
Michelle T Sun, Gala Beykin, Wen-Shin Lee, et al.
Investigative Ophthalmology & Visual Science
|
February 28, 2020
Association of a Variant in VWA3A with Response to Anti-Vascular Endothelial Growth Factor Treatment in Neovascular AMD
Michelle Grunin, Gala Beykin, Elior Rahmani, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 21, 2023
Genome-wide association study and genomic risk prediction of age-related macular degeneration in Israel
Michelle Grunin, Daria Triffon, Gala Beykin, et al.
Scientific Reports
|
June 6, 2024
Genome wide association study and genomic risk prediction of age related macular degeneration in Israel
Michelle Grunin, Daria Triffon, Gala Beykin, et al.
American Journal of Ophthalmology
|
November 15, 2021
Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes
Gala Beykin, Laurel Stell, Muhammad Sohail Halim, et al.
American Journal of Ophthalmology
|
August 17, 2022
Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234
Gala Beykin, Laurel Stell, Muhammad Sohail Halim, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Ophthalmology Science
|
May 8, 2026
Reply
Mariella Saludares, Zachary Wennberg-Smith, Gala Beykin, et al.
Ophthalmology Science
|
January 26, 2026
A Phase I Randomized Trial of Topical Insulin for Glaucoma: Safety and Efficacy Outcomes
Mariella Saludares, Zachary Wennberg-Smith, Gala Beykin, et al.
Investigative Ophthalmology & Visual Science
|
August 18, 2021
Analysis of the Aqueous Humor Proteome in Patients With Age-Related Macular Degeneration
Batya Rinsky, Gala Beykin, Michelle Grunin, et al.
Journal of Glaucoma
|
June 13, 2022
Structural and Metabolic Imaging After Short-term Use of the Balance Goggles System in Glaucoma Patients: A Pilot Study
Michelle T Sun, Gala Beykin, Wen-Shin Lee, et al.
Investigative Ophthalmology & Visual Science
|
February 28, 2020
Association of a Variant in VWA3A with Response to Anti-Vascular Endothelial Growth Factor Treatment in Neovascular AMD
Michelle Grunin, Gala Beykin, Elior Rahmani, et al.
Medrxiv : the Preprint Server for Health Sciences
|
September 21, 2023
Genome-wide association study and genomic risk prediction of age-related macular degeneration in Israel
Michelle Grunin, Daria Triffon, Gala Beykin, et al.
Scientific Reports
|
June 6, 2024
Genome wide association study and genomic risk prediction of age related macular degeneration in Israel
Michelle Grunin, Daria Triffon, Gala Beykin, et al.
American Journal of Ophthalmology
|
November 15, 2021
Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes
Gala Beykin, Laurel Stell, Muhammad Sohail Halim, et al.
American Journal of Ophthalmology
|
August 17, 2022
Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234
Gala Beykin, Laurel Stell, Muhammad Sohail Halim, et al.
Page
of 2